Skip to main content
SpringerLink
Log in

Promotion of a Lifelong Immunization Program for Healthy Ageing

  • Chapter
  • First Online:
Prevention of Chronic Diseases and Age-Related Disability

Part of the book series: Practical Issues in Geriatrics ((PIG))

  • 824 Accesses

Abstract

Ageing, frailty, and comorbidity increase the susceptibility to infections and enhance the consequences (morbidity, mortality, and costs) of these infections. Tetanus, pertussis, diphtheria, influenza, pneumococcal disease, and herpes zoster are vaccine preventable diseases (VPDs) frequently occurring in the older population. Immunity against these infections needs to be acquired early in life and tends to wane at higher ages (immunosenescence). During life vaccines can offer protection against VPD directly to the vaccinated person but also indirectly to non-vaccinated persons by herd protection. Vaccine formulations and strategies need to be adapted to yield a long-lasting protection against VPD. Integration of vaccines in a lifelong vaccination program offers the best possibility to obtain this goal. Yet, vaccination uptake in the (older) adult population is inconsistent or low. Vaccination implementation is complex and needs coordination between vaccine recipients, healthcare professionals, and the healthcare systems to improve vaccination coverage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization (2017) http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/tetanus_coverage.jpg?ua=1. Accessed Sept 2017

  2. Centers for Disease Control and Prevention (2011) VPD Surveillance Manual, 5th edn. Tetanus: Chapter 16–1. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.pdf. Accessed Sept 2017

  3. Williams WW, Lu PJ, O’Halloran A et al (2015) Vaccination coverage among adults, excluding influenza vaccination—United States, 2013. MMWR Morb Mortal Wkly Rep 64:95–102

    PubMed  PubMed Central  Google Scholar 

  4. WHO immunization, vaccines and biologicals: Diphteria. http://www.who.int/immunization/monitoring_surveillance/burden/diphtheria/en/

  5. Edmunds WJ, Pebody RG, Aggerback H et al (2000) The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiol Infect 125:113–125

    Article  CAS  Google Scholar 

  6. WHO immunization, vaccines and biologicals: Pertussis: http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis/en/

  7. Ridda I, Yin JK, King C et al (2012) The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly. Vaccine 30:6745–6752

    Article  Google Scholar 

  8. Williams WW, Lu PJ, O’Halloran A et al (2017) Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ 66:1–28

    Article  Google Scholar 

  9. Van Damme P, Burgess M (2004) Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine 22:305–308

    Article  Google Scholar 

  10. Fleming DM, Taylor RJ, Haguinet F et al (2016) Influenza-attributable burden in United Kingdom primary care. Epidemiol Infect 144:537–547

    Article  CAS  Google Scholar 

  11. Vestergaard LS, Nielsen J, Krause TG et al (2017) Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro Surveill 22:30506. https://doi.org/10.2807/1560-7917.ES.2017.22.14.30506

    Article  PubMed  PubMed Central  Google Scholar 

  12. ECDC technical report: seasonal influenza vaccination Europe 2012–13. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf

  13. Poscia A, Stojanovic J, Ricciardi W (2016) The sustainability of influenza vaccination programs: considerations and perspectives from Italy. J Prev Med Hyg 57:E9–E12

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Wetenschappelijk Instituut Volksgezondheid, Gezondheidsenquête 2013, rapport 5: preventie. https://his.wiv-isp.be/nl/Gedeelde%20%20documenten/VA_NL_2013.pdf

  15. Centers for Disease Control and Prevention (1998 to 2015) Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae

    Google Scholar 

  16. WHO (2012) Pneumococcal vaccines WHO position paper—2012. Wkly Epidemiol Rec 87:129–144 http://www.who.int/wer/2012/wer8714.pdf?ua=1

    Google Scholar 

  17. Public Health England (2017) Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2016 to March 2017. Health Protect Rep 11:23 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/624133/hpr2317_PPV.pdf

    Google Scholar 

  18. Black CL, Williams WW, Warnock R et al (2017) Pneumococcal vaccination among Medicare beneficiaries occurring after the advisory committee on immunization practices recommendation for routine use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults aged ≥65 years. MMWR Morb Mortal Wkly Rep 66:728–733

    Article  Google Scholar 

  19. Schröder C, Enders D, Schink T et al (2017) Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect 75:207–215

    Article  Google Scholar 

  20. Drolet M, Brisson M, Schmader KE et al (2010) The impact of herpes zoster and post-herpetic neuralgia on health-related quality of life: a prospective study. CMAJ 182:1731–1736

    Article  Google Scholar 

  21. McLaughlin JM, McGinnis JJ, Tan L et al (2015) Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev 36:259–273

    Article  Google Scholar 

  22. Chen WH, Kozlovsky BF, Effros RB et al (2009) Vaccination in the elderly: an immunological perspective. Trends Immunol 30:351–359

    Article  Google Scholar 

  23. Yao X, Hamilton RG, Weng NP et al (2011) Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 29:5015–5021

    Article  Google Scholar 

  24. Van Epps P, Tumpey T, Pearce MB et al (2017) Preexisting immunity, not frailty phenotype, predicts influenza postvaccination titers among older veterans. Clin Vaccine Immunol 24:e00498

    PubMed  PubMed Central  Google Scholar 

  25. Falkenhorst G, Remschmidt C, Harder T et al (2017) Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One 12:e0169368

    Article  Google Scholar 

  26. van Werkhoven CH, Huijts SM, Bolkenbaas M et al (2015) The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis 61:1835–1838

    Article  Google Scholar 

  27. Nunzi E, Iorio AM, Camilloni B (2017) A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 y.o.) institutionalized subjects. Hum Vaccin Immunother 13(11):2659–2668. https://doi.org/10.1080/21645515.2017.1373226

    Article  PubMed  PubMed Central  Google Scholar 

  28. Jackson ML, Chung JR, Jackson LA et al (2017) Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 377:534–543

    Article  Google Scholar 

  29. Castilla J, Guevara M, Martínez-Baz I et al (2015) Enhanced estimates of the influenza vaccination effect in preventing mortality: a prospective cohort study. Medicine (Baltimore) 94:e1240

    Article  Google Scholar 

  30. Oxman MN, Levin MJ, Johnson GR et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284

    Article  CAS  Google Scholar 

  31. Cunningham AL, Lal H, Kovac M et al (2016) Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375:1019–1032

    Article  CAS  Google Scholar 

  32. Van Damme P, McIntyre P, Grimprel E et al (2011) Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 29:5932–5939

    Article  Google Scholar 

  33. Lang PO, Aspinall R (2014) Vaccination in the elderly: what can be recommended? Drugs Aging 31:581–589

    Article  CAS  Google Scholar 

  34. Grohskopf LA, Sokolow LZ, Broder KR et al (2017) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2017-18 Influenza Season. MMWR Recomm Rep 66:1–20

    Article  Google Scholar 

  35. Bonanni P, Azzari C, Castiglia P et al (2014) The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Health. Italian Society of Pediatrics. Italian Federation of Pediatric Physicians. Italian Federation of General Medical Physicians. Arezzo Service of Legal Medicine. Epidemiol Prev 38:131–146

    PubMed  Google Scholar 

  36. Bonanni P, Bonaccorsi G, Lorini C et al (2017) Focusing on the implementation of 21st century vaccines for adults. Vaccine. pii: S0264-410X(17)31036–8. [Epub ahead of print]. https://doi.org/10.1016/j.vaccine.2017.07.100

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatric Medicine, UZ Leuven, Leuven, Belgium

    Johan Flamaing

  2. Division of Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism, and Ageing (CHROMETA), KU Leuven, Leuven, Belgium

    Johan Flamaing

Authors
  1. Johan Flamaing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johan Flamaing .

Editor information

Editors and Affiliations

  1. Geneva University, Geneva, Switzerland

    Jean-Pierre Michel

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Flamaing, J. (2019). Promotion of a Lifelong Immunization Program for Healthy Ageing. In: Michel, JP. (eds) Prevention of Chronic Diseases and Age-Related Disability. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-319-96529-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96529-1_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96528-4

  • Online ISBN: 978-3-319-96529-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation